RetinoStat® Gene Therapy for the Treatment of Wet AMD: Oxford BioMedica


Description: Oxford BioMedica (U.K.) is conducting a Phase I clinical trial of RetinoStat® for the treatment of wet age-related macular degeneration (AMD). The treatment involves the delivery of a gene that produces a protein which halts the production of vascular endothelial growth factor (VEGF). VEGF is a protein that leads to the proliferation of leaky blood vessels underneath the retina that causes vision loss in wet AMD. A lentivisrus is used for gene delivery. As many as 18 participants will be enrolled in the study. Three doses of the treatment are being evaluated.

Trial Status: Recruiting participants.


Clinical Trial for Wet AMD Gene Therapy to Begin in December 2010

Partial List of Participation Criteria:

  1. 50 years of age or older
  2. Diagnosis of wet age-related macular degeneration

Clinical Contact:
Peter Campochiaro, M.D.
Johns Hopkins University Hospital
Baltimore, MD

Additional Information:
RetinoStat clinical trial listing on